» Articles » PMID: 18780827

Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods: Recommendations for Measuring Relative Cerebral Blood Volume in Brain Tumors

Overview
Journal Radiology
Specialty Radiology
Date 2008 Sep 11
PMID 18780827
Citations 167
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate whether estimates of relative cerebral blood volume (rCBV) in brain tumors, obtained by using dynamic susceptibility-weighted contrast material-enhanced magnetic resonance (MR) imaging vary with choice of data acquisition and postprocessing methods.

Materials And Methods: Four acquisition methods were used to collect data in 22 high-grade glioma patients, with informed written consent under HIPAA-compliant guidelines approved by the institutional review board. During bolus administration of a standard single dose of gadolinium-based contrast agent (0.1 mmol per kilogram of body weight), one of three acquisition methods was used: gradient-echo (GRE) echo-planar imaging (echo time [TE], 30 msec; flip angle, 90 degrees ; n = 10), small-flip-angle GRE echo-planar imaging (TE, 54 msec; flip angle, 35 degrees ; n = 7), or dual-echo GRE spiral-out imaging (TE, 3.3 and 30 msec; flip angle, 72 degrees ; n = 5). Next, GRE echo-planar imaging (TE, 30 msec; flip angle, 90 degrees ; n = 22) was used to collect data during administration of a second dose of contrast agent (0.2 mmol/kg). Subsequently, six methods of analysis were used to calculate rCBV. Mean rCBV values from whole tumor, tumor hot spots, and contralateral brain were normalized to mean rCBV in normal-appearing white matter.

Results: Friedman two-way analysis of variance and Kruskal-Wallis one-way analysis of variance results indicated that qualitative rCBV values were dependent on acquisition and postprocessing methods for both tumor and contralateral brain. By using the nonparametric Mann-Whitney test, a consistently positive (greater than zero) tumor-contralateral brain rCBV ratio resulted when either the preload-postprocessing correction approach or dual-echo acquisition approach (P < .008 for both methods) was used.

Conclusion: The dependence of tumor rCBV on the choice of acquisition and postprocessing methods is caused by their varying sensitivities to T1 and T2 and/or T2* leakage effects. The preload-correction approach and dual-echo acquisition approach are the most robust choices for the evaluation of brain tumors when the possibility of contrast agent extravasation exists.

Citing Articles

Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.

Gough R, Treffy R, Krucoff M, Desai R Cancers (Basel). 2025; 17(1.

PMID: 39796751 PMC: 11720166. DOI: 10.3390/cancers17010124.


Comparison of normalized cerebral blood flow between different post-processing methods of dynamic susceptibility contrast perfusion-weighted imaging and arterial spin labeling in gliomas with different grading.

Wang C, Liu F, Zhang L, Song Y, Pan Z, Li G Quant Imaging Med Surg. 2024; 14(12):8720-8733.

PMID: 39698595 PMC: 11652009. DOI: 10.21037/qims-24-1076.


DSC-PWI presurgical differentiation of grade 4 astrocytoma and glioblastoma in young adults: rCBV percentile analysis across enhancing and non-enhancing regions.

Pons-Escoda A, Naval-Baudin P, Viveros M, Flores-Casaperalta S, Martinez-Zalacain I, Plans G Neuroradiology. 2024; 66(8):1267-1277.

PMID: 38834877 PMC: 11246293. DOI: 10.1007/s00234-024-03385-0.


Identification of a Single-Dose, Low-Flip-Angle-Based CBV Threshold for Fractional Tumor Burden Mapping in Recurrent Glioblastoma.

Anil A, Stokes A, Karis J, Bell L, Eschbacher J, Jennings K AJNR Am J Neuroradiol. 2024; 45(10):1545-1551.

PMID: 38782593 PMC: 11448978. DOI: 10.3174/ajnr.A8357.


An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI.

Garcia-Ruiz A, Pons-Escoda A, Grussu F, Naval-Baudin P, Monreal-Aguero C, Hermann G Cell Rep Med. 2024; 5(3):101464.

PMID: 38471504 PMC: 10983037. DOI: 10.1016/j.xcrm.2024.101464.


References
1.
Jackson A . Analysis of dynamic contrast enhanced MRI. Br J Radiol. 2005; 77 Spec No 2:S154-66. DOI: 10.1259/bjr/16652509. View

2.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

3.
Maeda M, Itoh S, Kimura H, Iwasaki T, Hayashi N, Yamamoto K . Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology. 1993; 189(1):233-8. DOI: 10.1148/radiology.189.1.8372199. View

4.
Henson J, Ulmer S, Harris G . Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol. 2008; 29(3):419-24. PMC: 8118884. DOI: 10.3174/ajnr.A0963. View

5.
Belliveau J, Rosen B, KANTOR H, Rzedzian R, Kennedy D, McKinstry R . Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med. 1990; 14(3):538-46. DOI: 10.1002/mrm.1910140311. View